NDC-0524 for Parkinson’s may enter clinical testing in late 2025
NDC-0524, an experimental antibody that Nitrase Therapeutics is developing as a treatment for people with Parkinson’s disease, is expected to enter clinical testing in the fourth quarter of 2025, or before the end of the year, according to a company press release. The antibody, which targets nitrated…